- Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - ASCO - J. Clin. Oncol. - 2008
- Abstract - Primary - Primary - Respiratory - NCCTG-N0426
A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.
There are 255 items
TCR Sequencing to Identify Responders in Patients with Stage III NSCLC Treated with Atezoluzimab with Chemoradiation (AFT-16).
Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC
Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (ppembro) and standard platinum-based chemotherapy (chemo) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) AFT-09 (Alliance)
Tolerability of veliparib (V) in combination with carboplatin (C)/paclitaxel (P) - based chemoradiotherapy (CRT) in subjects with stage III non-small cell lung cancer (NSCLC).
Veliparib (Vel) in Combination with Chemoradiotherapy (CRT) of Carboplatin/Paclitaxel (C/P) Plus Radiation in Patients With Stage III Non-Small Cell Lung Cancer (NSCLC) (AFT-07).
